Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

A proof-of-concept gene-editing trial for the treatment of prion diseases

EF 2022-23

Résumé
Prion disorders are rapidly progressing, invariably fatal, neurodegenerative diseases of mammals that include Creutzfeldt-Jakob Disease in humans. The culprit in these diseases is a specific abnormally folded protein, termed the Scrapie prion protein (PrPSc). Exposure to PrPSc can come from contaminated food sources or inherited defects in the human prion gene that increase the propensity of PrPSc to form. Once present, PrPSc induces the normal cellular prion protein (PrPC) present in most cells to acquire themselves the abnormal PrPSc fold. As toxic PrPSc prions spread and deposit throughout the brain, cells die, and sponge-like holes emerge. Proof-of-concept data in mice established that reducing PrPC levels can profoundly extend prion disease survival by slowing PrPSc amplification. Moreover, mice and cattle with ablated prion genes are healthy, indicating that it is safe to reduce PrPC levels. Regrettably, approaches to date require repeated lumbar punctures and may not scale to human brains. In recent years, a powerful gene-editing technology, known as CRISPR-Cas, has come to the fore. I hypothesize that this technology can be harnessed for prion disease therapy by designing a bespoke gene therapy. To this end, I will pack the necessary components into a non-pathogenic shell, derived from adeno-associated viruses (AAV). I will optimize this AAVs for delivery to brain cells known to produce PrPC and for being most active in them. Next, I will quantify how well this system ablates the prion gene, initially in brain-like cells in the dish, before moving to similar studies in mice. If this pre-clinical program is successful, it may not be long before it can enter the clinic because no other therapy exists that can extend the survival of patients with prion disease.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486043
Name
Verkuyl Claire E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A proof-of-concept gene-editing trial for the treatment of prion diseases
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adeno-Associated Virus (Aav) Vector; Creutzfeldt-Jakob Disease; Crispr-Cas9; Gene-Editing; Prion Disorders; Therapeutic
Abstract
Prion disorders are rapidly progressing, invariably fatal, neurodegenerative diseases of mammals that include Creutzfeldt-Jakob Disease in humans. The culprit in these diseases is a specific abnormally folded protein, termed the Scrapie prion protein (PrPSc). Exposure to PrPSc can come from contaminated food sources or inherited defects in the human prion gene that increase the propensity of PrPSc to form. Once present, PrPSc induces the normal cellular prion protein (PrPC) present in most cells to acquire themselves the abnormal PrPSc fold. As toxic PrPSc prions spread and deposit throughout the brain, cells die, and sponge-like holes emerge. Proof-of-concept data in mice established that reducing PrPC levels can profoundly extend prion disease survival by slowing PrPSc amplification. Moreover, mice and cattle with ablated prion genes are healthy, indicating that it is safe to reduce PrPC levels. Regrettably, approaches to date require repeated lumbar punctures and may not scale to human brains. In recent years, a powerful gene-editing technology, known as CRISPR-Cas, has come to the fore. I hypothesize that this technology can be harnessed for prion disease therapy by designing a bespoke gene therapy. To this end, I will pack the necessary components into a non-pathogenic shell, derived from adeno-associated viruses (AAV). I will optimize this AAVs for delivery to brain cells known to produce PrPC and for being most active in them. Next, I will quantify how well this system ablates the prion gene, initially in brain-like cells in the dish, before moving to similar studies in mice. If this pre-clinical program is successful, it may not be long before it can enter the clinic because no other therapy exists that can extend the survival of patients with prion disease.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Verkuyl, Claire E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~